PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Category:
Sort By:
Aug 10, 2018
Aug 10, 2018

byncaipen

Ophthalmology

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) has entered into the 3rd phase of testing in retinal cell replacement therapy at the University of British Columbia. Due to the positive results from the first two phases of testing where the AAGP® treated cells showed a dramatic increase in survivability versus untreated cells...Read more
Jun 13, 2018
Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is pleased to announce that it has executed a Material Transfer Agreement (MTA) with a reputed biotechnology company having a number of worldwide offices on four continents. Under the MTA, ProtoKinetix and this company are working together to test the effects AAGP® have on three...Read more
Jan 10, 2018
Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX)  is pleased to announce that it has entered into a research agreement with The University of British Columbia (UBC), under the direction of principal investigator Dr. Kelly McNagny, Professor, Faculty of Medicine, Department of Medical Genetics. Dr. Kelly McNagny Bio This research agreement is to...Read more
Nov 16, 2017
Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is pleased to provide a scientific update on immune cell banking and functions relevant to immunotherapy using AAGP® in collaboration with Proactive Immune Sciences. Earlier in 2017, Proactive initiated a research program which utilized an anti-aging glycopeptide (AAGP®) produced by ProtoKinetix Inc. which, amongst other...Read more
Oct 17, 2017
Belpre, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) is pleased to provide a scientific update to its stockholders. The Company is exploring the following areas for the use of its AAGP® family of molecules: Presently at the University of Alberta: 1. Diabetes (study started February 2017)  The PKX-001 (AAGP®’s clinical name) Study is treating...Read more
Jun 05, 2017
St. Marys, West Virginia ProtoKinetix, Incorporated (PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) and Proactive Immune Sciences (www.proactiveimmunesciences.com) today announce that they have entered into a joint research collaboration. The goal of the research will be to test the effect of the patented anti-aging glycopeptide AAGP® on the immune cell cryopreservation protocols used by Proactive Immune Sciences....Read more
May 24, 2017
About ProtoKinetix, Incorporated ProtoKinetix, Incorporated (OTC: PKTX) (the  “Company” or “ProtoKinetix”) (www.protokinetix.com) today announces that it has completed the first year of retinal replacement therapy trials on animals and the results are encouraging enough to proceed to a second phase of testing. There are several diseases that, over time, destroy retinal cells ultimately causing blindness....Read more
Mar 09, 2017
St. Marys, West Virginia ProtoKinetix, Incorporated (OTC: PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) today announced the start of a Phase 1 first-in-human clinical trial of AAGP® PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment of Type 1 diabetes. The first patient has been treated under this protocol.  The trial...Read more
Feb 07, 2017
St. Marys, West Virginia ProtoKinetix, Incorporated (OTC: PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) updates its stockholders on the testing of neuronal retinal cells in living tissue at the University of British Columbia (“UBC”) under the guidance of Dr. Gregory-Evans. As explained by Dr. Gregory-Evans, the research program at UBC will be determining whether AAGP® can...Read more
Jan 24, 2017
St. Marys, West Virginia ProtoKinetix, Incorporated (PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) today announced that the Governors of the University of Alberta have received a “No Objection Letter” from Health Canada to its Clinical Trial Application entitled: “Clinical Study using Antiaging Glycopeptide (PKX-001) in Islet Transplantation”. This authorization will allow the clinical trial group to...Read more

Subscribe for updates

Get alerts about company news and key findings directly in your inbox.

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.

Picture of a molecule
Picture of a molecule